^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Lymphocytic Lymphoma
    Drug:Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    AstraZeneca Press Release
    Title:

    Calquence approved in China for chronic lymphocytic leukaemia

    Published date:
    09/04/2023
    Excerpt:
    AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    AstraZeneca Press Release
    Title:

    Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

    Published date:
    01/25/2021
    Excerpt:
    AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]).
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with:...Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL without del(17p)/TP53 mutation, First-line therapy, Frail patient with significant comorbidity…Acalabrutinib ± obinutuzumab was changed from a category 2A recommendation to a category 1 recommendation.